U.S. Customs restrain Olympus medical equipment from importation, following FDA orders
The Food and Drug Administration (FDA) has imposed an import alert on certain Olympus Medical devices, preventing them from entering the United States. The alert, issued on June 24, 2025, affects 58 specific models of devices used in urinary, respiratory, abdominal, and pelvic procedures, including ureterorenoscopes, bronchoscopes, laparoscopes, and automated endoscope reprocessors [1][2][4].
The FDA's action follows multiple warning letters sent to Olympus from November 2022 to March 2023, citing serious noncompliance with manufacturing quality system regulations and a "troubling disregard for patient safety" [1][2]. Despite Olympus' efforts to address these issues, the FDA states that concerns remain outstanding.
Healthcare providers in the U.S. may continue using existing Olympus devices if they are functioning properly and not damaged or failing leak tests. However, future imports of the restricted devices are refused entry until the FDA is satisfied with corrective measures [1][2][3]. The FDA continues to work with Olympus to expedite corrective actions and minimize patient risk.
Olympus has committed to resolving these compliance issues by the end of its fiscal year 2026 (ending March 31, 2026), spending significant resources on a regulatory transformation project. The company expects to complete its commitments to the FDA by the end of its 2026 fiscal year [1][3][4].
Recent leadership changes have occurred at Olympus, with former Medtronic executive Bob White assuming the CEO role on June 1, 2025. The import alert currently only affects U.S. imports and does not impact device shipments to other countries [1][3][4].
This ongoing regulatory challenge underscores the FDA's focus on patient safety and manufacturing quality in medical device imports. The FDA advises against using damaged devices or those that fail a leak test, but has not provided a specific timeline for the lifting of the import alerts on Olympus devices [1][2]. Additionally, the FDA has not approved any new Olympus Medical devices for entry into the U.S. since the import alerts were issued, nor has it provided any updates on the status of the three warning letters sent to Olympus from November 2022 to March 2023.
[1] FDA News Release: FDA issues import alert for certain Olympus medical devices due to quality system failings. (2025, June 24). Retrieved July 1, 2025, from https://www.fda.gov/news-events/press-announcements/fda-issues-import-alert-certain-olympus-medical-devices-due-quality-system-failings
[2] Olympus News Release: Olympus Statement on FDA Import Alert. (2025, June 24). Retrieved July 1, 2025, from https://olympus-global.com/en/news/2025/06/24/121031.html
[3] FDA News Release: FDA sends warning letters to Olympus for serious violations of manufacturing quality system regulations. (2023, March 30). Retrieved July 1, 2025, from https://www.fda.gov/news-events/press-announcements/fda-sends-warning-letters-olympus-serious-violations-manufacturing-quality-system-regulations
[4] Olympus News Release: Olympus Announces Major Initiatives for Regulatory Transformation. (2025, April 29). Retrieved July 1, 2025, from https://olympus-global.com/en/news/2025/04/29/120967.html
- The Food and Drug Administration (FDA) has imposed an import alert on certain Olympus Medical devices, citing regulatory noncompliance and a disregard for patient safety.
- The FDA's action follows multiple warning letters sent to Olympus, highlighting concerns about manufacturing quality system regulations.
- The FDA continues to work with Olympus to ensure corrective measures are implemented to address these compliance issues.
- Olympus has committed to resolving these issues by the end of their fiscal year 2026, spending significant resources on a regulatory transformation project.
- The import alert affects 58 specific models of devices used in various medical procedures and does not currently impact device shipments to other countries.
- The FDA has not approved any new Olympus Medical devices for entry into the U.S. since the import alerts were issued, nor has it provided any updates on the status of the three warning letters sent to Olympus.
- The ongoing regulatory challenge underscores the FDA's focus on patient safety and manufacturing quality in medical device imports.
- The FDA advises against using damaged devices or those that fail a leak test, but has not provided a specific timeline for the lifting of the import alerts on Olympus devices.
